Tourbillon’s Big Short Pays Off in Q3

October 17, 2016   Stephen Taub

Read more:

Jason Karp’s firm posted a strong third quarter in part due to the collapsing price of a struggling biotech company.

Shares of biotechnology firm MannKind Corp., which specializes in therapeutic products for diabetes and has been in free fall lately, plummeted another 8 percent or so on Friday, to close at a new low of about $0.50 per share. This …


Subscribers have unlimited access to all online content inc rankings. Start your subscription today - click on the button below.

Subscribe now

Free trial

Taking a free trial will give you access to online content one week (excludes research & rankings). Start your trial today.

Free Trial


Planning for a high-income year due to 457A income? Download this short paper to find out more about the opportunity to reduce tax liability and have significant charitable impact..

Click here for more details.

Latest Poll

How will hedge funds finish 2017?

 - 71%
 - 21%
 - 7%

View previous results